A new trial analysis suggests that orforglipron, taken as a daily pill, could help some people maintain weight loss after they stop injectable weight-loss drugs (“jabs”). The reports describe the pill as a potential longer-term option to reduce the risk of regained weight and to prevent further progression from lower levels of overweight to obesity. Researchers say orforglipron works by affecting metabolic processes linked to appetite and digestion, including lowering blood sugar levels, slowing food digestion, and reducing appetite. The trial data also indicate a possible broader health impact: the researchers estimate orforglipron could help prevent more than 200 diseases associated with obesity. The outlets emphasize that the findings are based on trial results and that the pill is being positioned as a future option that may reduce the need for other long-term medications for obesity-related conditions. The reports do not provide details in the excerpts on the trial size, duration, or specific outcomes beyond the overall direction of the evidence.